about
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administrationTargeting CDK9: a promising therapeutic opportunity in prostate cancerTargeting Pim kinases for cancer treatment: opportunities and challengesThe association of socio-demographic status, lifestyle factors and dietary patterns with total urinary phthalates in Australian menEnantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography.Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.Cohort profile: The men androgen inflammation lifestyle environment and stress (MAILES) studyMyrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine.MAP kinase-interacting kinases--emerging targets against cancer.Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexilineInhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cellsHighly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.Unveiling new chemical scaffolds as Mnk inhibitors.Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver.Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature.Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions.Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney.The quantification of paracetamol, paracetamol glucuronide and paracetamol sulphate in plasma and urine using a single high-performance liquid chromatography assay.Stereoselective hepatic disposition of model diastereomeric acyl glucuronides.Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds.Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.CDK5 in oncology: recent advances and future prospects.Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography.Effect of CYP2D6 metabolizer status on the disposition of the (+) and (???) enantiomers of perhexiline in patients with myocardial ischaemiaComparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tabletsComparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pigHepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothaleinCYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomesOral L-carnitine: metabolite formation and hemodialysisLoading-washout studies of the stereoselective sinusoidal uptake of (R)- and (s)-2-phenylpropionyl acyl glucuronide
P50
Q24682618-7ED41BAF-5EF6-49C7-8075-372B52EB56D2Q28073701-CE08386B-84BE-4BF7-A33A-C4B5A4DE45E3Q28255361-95C80817-C848-4BD0-AFC1-DC095C813795Q28391859-605EF8E9-9695-4B86-B4B1-9B1E6B12D1DFQ31030469-E8F8D832-4F14-4E5E-96FF-D8531182CBA0Q33976935-13F573F8-3E34-4A97-96C5-67607EAD6860Q34122854-252F4A08-7475-45C6-9EA8-4B04BE138499Q34560321-C4BE2E23-CD48-4ED4-B1DA-9A2689B9841DQ34649141-24D5AF49-6152-47CA-85BA-D4EC674D0C69Q34700588-6EFDD27F-6011-4CB0-931B-F90E3A2836E0Q35115824-CA160E1E-6DFE-4BB2-860C-F4A2B0D260FDQ36535908-23F2DE40-D4A5-4143-9CAE-0038A1CE9B8FQ37636705-BCECA1AC-6E79-49B9-82FB-7DEB6D07410CQ38718161-4C7CC18A-3C4C-4873-A2FE-EABA365ECBE8Q38791406-82D3DE1B-E8B0-4A55-B913-F99C34E62F98Q39010703-807992DD-CB86-4B86-B4B0-76E1A81B21E2Q39029676-117C664A-5CA8-4004-8676-33CB10B488BDQ39476552-1CA97501-7040-4873-87A1-2EBA692E6037Q39743535-B020632D-A98D-45E9-AF2A-99FFD01D423CQ41170052-6DBB20A6-2871-46FB-8384-4EF579B22E7EQ43287018-AE98980E-D4B1-4555-8AC5-631C13A7EBFCQ44435147-6A493602-8C21-482A-A677-CC9C95280787Q44452953-FADEB062-B207-4F44-ACBE-081BAFC1429EQ44738488-3B8A3381-2486-494E-B292-F990A43C32C4Q44884229-35147246-6854-4663-8CD7-6BFEA3DD5849Q45043533-6BE6E1DA-764D-4F57-820C-C48B3B7CD66EQ45114740-408C4386-80EF-451F-BB38-81E005BFBAE4Q46786476-12590661-E6DD-4649-8B98-697A28FD2D4CQ46886063-335450C3-69A9-45B4-9EA9-8AC5D05B5F0BQ47869626-49C86378-BF3F-4F0A-B185-825F1E3B517EQ47873426-B43816BC-07D2-4276-A134-A831D6818650Q51141618-4A283BB1-99E7-49EB-B097-61C528B3136BQ53006904-02102497-029D-4E32-87B1-654FDD300393Q61311927-AC3580EC-605A-4E88-9B88-6A3EC89244CEQ67030175-7F120018-E148-4BB2-ACC1-25AEA24A46A4Q73654383-69CD28B9-D7D6-4DF8-BFE6-4B7BAF6F1364Q73755569-11FA5BA4-C506-4867-A2CA-7A9A1AFBFDDBQ79271712-F0CA0860-2F1B-49FF-BCF0-0C7A99D9D975Q79315892-057D1937-7D75-42A8-8EAD-8B809B9AEA60Q79315894-F74CF532-104F-49ED-A802-20DBC4AABD62
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Milne
@ast
Robert Milne
@en
Robert Milne
@es
Robert Milne
@nl
Robert Milne
@sl
type
label
Robert Milne
@ast
Robert Milne
@en
Robert Milne
@es
Robert Milne
@nl
Robert Milne
@sl
prefLabel
Robert Milne
@ast
Robert Milne
@en
Robert Milne
@es
Robert Milne
@nl
Robert Milne
@sl
P106
P1153
7202122471
P21
P31
P496
0000-0002-4554-8366